Purpose: To investigate the effect on surface dose, as a function of different field sizes and distances from the solid water phantom to transmission detector (D), of using the monolithic silicon detector MP512T in transmission mode.
Methods: The influence of operating the MP512T in transmission mode on the surface dose of a phantom for SSD 100cm was evaluated by using a Markus IC. The MP512T was fixed to an adjustable stand holder and was positioned at different D, ranging from 0.3 to 24 cm. For each D, measurements were carried out for irradiation field sizes of 5 × 5cm, 8 × 8 cm and 10 × 10 cm. Measurements were obtained under two different operational setups, (i) with the MP512T face-up and (ii) with the MP512T face-down. In addition, the transmission factors for the MP512T and the printed circuit board were only evaluated using a Farmer IC.
Results: For all D and all field sizes, the MP512T led to the surface dose increasing by less than 25% when in the beam. For D >18 cm the surface dose increase is less than 5%, and negligible for field size 5 × 5 cm. The difference in the surface dose perturbation for the MP512T operating face up or operating face down is negligible (<2%) for all field sizes. The transmission factor of the MP512T ranged from 1.020 to 0.9950 for all measured D and field sizes.
Conclusion: The study demonstrated that positioning the MP512T in air between the Linac head and the phantom produced negligible perturbation of the surface dose for D >18 cm, and was completely transparent for 6 MV photon beams.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejmp.2017.10.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours.
BMJ Oncol
May 2024
Sarah Cannon Cancer Institute, Nashville, Tennessee, USA.
Objective: The arginase inhibitor INCB001158 was evaluated for safety (primary endpoint) in locally advanced or metastatic solid tumours; pharmacokinetics, pharmacodynamics and efficacy were also assessed.
Methods And Analysis: In this non-randomised, open-label, three-part phase 1 study, INCB001158 was orally administered two times per day as monotherapy or in combination with intravenous pembrolizumab 200 mg every 3 weeks. Dose expansion was conducted in tumour-type cohorts (with or without prior anti-PD-1/PD-L1 (programmed death protein 1/programmed death ligand 1) therapy).
Extracellular vesicle surface engineering with integrins (ITGAL & ITGB2) to specifically target ICAM-1-expressing endothelial cells.
J Nanobiotechnology
January 2025
Krefting Research Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Extracellular vesicles (EVs) are taken up by most cells, however specific or preferential cell targeting remains a hurdle. This study aims to develop an EV that targets cells involved in inflammation, specifically those expressing intercellular adhesion molecule-1 (ICAM-1). To target these cells, we overexpress the ICAM-1 binding receptor "lymphocyte function-associated antigen-1" (LFA-1) in HEK293F cells, by sequential transfection of plasmids of the two LFA-1 subunits, ITGAL and ITGB2 (CD11a and CD18).
View Article and Find Full Text PDFDomperidone inhibits dengue virus infection by targeting the viral envelope protein and nonstructural protein 1.
Sci Rep
January 2025
Siriraj Center of Research Excellence in Dengue and Emerging Pathogens, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Dengue is a mosquito-borne disease caused by dengue virus (DENV) infection, which remains a major public health concern worldwide owing to the lack of specific treatments or antiviral drugs available. This study investigated the potential repurposing of domperidone, an antiemetic and gastrokinetic agent, to control DENV infection. Domperidone was identified by pharmacophore-based virtual screening as a small molecule that can bind to both the viral envelope (E) and the nonstructural protein 1 (NS1) of DENV.
View Article and Find Full Text PDFEffect of two novel GABAA receptor positive allosteric modulators on neuropathic and inflammatory pain in mice.
Neuropharmacology
January 2025
Department of Pharmacy, Nanjing First Hospital, Nanjing Medical University, Nanjing, China; School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China. Electronic address:
Loss of GABAergic inhibition in the spinal dorsal horn (SDH) is implicated in central sensitization and chronic pain. Both agonists and positive allosteric modulators (PAMs) of GABAA receptor are found to be effective in the management of chronic pain. In addition to benzodiazepines, neuroactive steroids (NASs) also act as PAMs through binding to unique sites of GABAA receptors.
View Article and Find Full Text PDFNondeterministic dynamics in the η-to-θ phase transition of alumina nanoparticles.
Science
January 2025
Department of Chemistry, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Phase diagrams and crystallography are standard tools for studying structural phase transitions, whereas acquiring kinetic information at the atomistic level has been considered essential but challenging. The η-to-θ phase transition of alumina is unidirectional in bulk and retains the crystal lattice orientation. We report a rare example of a statistical kinetics study showing that for nanoparticles on a bulk Al(OH) surface, this phase transition occurs nondeterministically through an ergodic equilibrium through the molten state, and the memory of the lattice orientation is lost in this process.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!